论文信息 - Serum biomarker in neurofibromatosis type 1. - 字舞流文

Serum biomarker in neurofibromatosis type 1.

T. Horie | Y. Yoshida | O. Yamamoto | M. Furumura | M. Tahira

[1] S. Mundlos,et al. MIA is a potential biomarker for tumour load in neurofibromatosis type 1 , 2011, BMC medicine.

[2] K. Adachi,et al. Local mast cell histamine and plasma histamine levels in neurofibromatosis type 1. , 2010, Acta dermato-venereologica.

[3] A. Bosserhoff,et al. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes. , 2005, Pigment cell research.

[4] J. Lambert,et al. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. , 2005, Pigment cell research.

[5] A. Bosserhoff,et al. Elevated MIA levels in the serum of pregnant women and of children , 2004, Clinical and experimental dermatology.

[6] O. Dereure,et al. Cutaneous malignant melanoma and neurofibromatosis type 1 , 2004, Melanoma research.

[7] G. Imokawa,et al. The mechanism of epidermal hyperpigmentation in café‐au‐lait macules of neurofibromatosis type 1 (von Recklinghausen's disease) may be associated with dermal fibroblast‐derived stem cell factor and hepatocyte growth factor , 2003, The British journal of dermatology.

[8] D. Burns,et al. Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[9] W. Stolz,et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.